🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PErsonalized Addition of Recombinant LH in Ovarian Stimulation

RecruitingPhase 4Ages 35 Years - 40 YearsFemaleFundación Santiago Dexeus Font
NCT04719000 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Different ovarian stimulation regimens have shown to modify late follicular phase hormonal profiles. Besides, recent studies confirm that progesterone levels and their variation in the last day of oocyte maturation are affected by the dose of gonadotropins administered and by other factors. Progesterone elevation in late follicular phase of in vitro fertilization/intracytoplasmatic sperm injection (IVF/ICSI) cycles under ovarian stimulation compromises implantation rates due to a negative effect on the endometrium. However, there is still conflict in the literature questioning whether progesterone levels alone on the triggering day is a sufficient indicator as progesterone does not give the full picture of the ovarian functions, number of follicles as well as estrogen production that facilitate endometrial growth, thus some studies suggest that especially in aged and poor responders Prog

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Able and willing to sign the Patient Consent Form and adhere to study visitation schedule. * ≥ 35 years ≤40 years old. * AFC ≥5 and or AMH ≥1.2 ng/mL. * \<4 or 4-9 oocytes retrieved in a previous IVF/ICSI cycle with a starting dose of ≤225 IU with any gonadotropin under a GnRH antagonist protocol. * Up to 3 previous ovarian stimulation cycles with a starting dose of ≤225 IU in which dose adjustments during stimulation did not exceed 300 IU. * Ovarian stimulation for IVF/ICSI Exclusion Criteria: * Poor ovarian responders according to the Bologna criteria. * Polycystic ovary syndrome (PCOS) patients according to the Rotterdam criteria. * AFC\>20. * Age \>40 or \<35 years old. * Women with \>10 oocytes retrieved in a previous IVF/ICSI cycle with 150-225 IU starting dose. * Women who required dose adjustments during stimulation \>300 IU with any gonadotropin in their previous cycle * Uterine abnormalities. * Recent history of any current untreated endocrine abnormality. * Unilateral or bilateral hydrosalpinx (visible on ultrasound scan (USS), unless clipped). * Contraindications for the use of medicine used for ovarian stimulation (gonadotropins, GnRH antagonist, progesterone vaginal gel) * Recent history of severe disease requiring regular treatment (Clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication to pregnancy). * Preimplantation Genetic Testing for Aneuploidies (PGT-a). * Testicular Sperm Aspiration or Testicular Sperm Extraction (TESA or TESE)
💊

What it tests

  • rhFSH+rhLH
  • rhFSH
📍

Where

1 site
Hospital Universitario Quiron Dexeus
Barcelona, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy